NCT00002166View on ClinicalTrials.gov

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Nevirapine

Trial Locations (1)

06877

Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00002166 - An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease | Biotech Hunter | Biotech Hunter